Skip to main content

Table 2 A total of 158 patients with JIA examined with panoramic radiographs

From: Temporomandibular condylar alterations in juvenile idiopathic arthritis most common in longitudinally severe disease despite medical treatment

 

Total

Condylar alterations

No condylar alterations

P

Total, n (% girls)

158 (73)

68 (78)

90 (70)

0.26

Duration, yrs, median (25/75th percentile)

2.5 (0.5/3.9)

2.8 (0.6/4.7)

2.3 (0.4/3.2)

0.21

“EU 1 any time”, n (%)

15 (9)

9 (13)

6 (7)

0.11

Number of “active disease periods”, median (25/75th percentile)

2.49 (1.0/3.0)

2.87 (1.0/4.0)

2.28 (1.0/3.0)

0.06

“Potent medication” any time, n (%)

75 (47)

41 (60)

34 (38)

0.01

Number of “medication periods”, median (25/75th percentile)

2.69 (1.0/4.0)

3.06 (1.0/4.0)

2.41 (1.0/3.0)

0.02

Both “MTX and TNF-alpha inhibitor” any time, n (%)

43 (27)

23 (34)

20 (22)

0.09

“EU 1 or potent medication” any time, n (%)

82 (52)

43 (63)

39 (43)

0.01

“EU 1 and potent medication” any time, n (%)

15 (10)

11 (16)

4 (4)

0.02

  1. The association between condylar alterations, longitudinal disease activity and medication is presented. The bold values of column P is statistically significant (P =< 0.05).
  2. Condylar alterations = shape or structural.
  3. Duration = time from onset (yrs), as judged by the rheumatologist, to the panoramic examination.
  4. “EU 1 any time” = active disease with increasing number of active joints any time for at least six months between onset and the panoramic examination.
  5. Number of “active disease periods” = EU 1 and/or EU 2 (stable disease with unchanged number of active joints) for six months or more between onset and the panoramic examination.
  6. “Potent medication” = MTX and/or TNF-alpha inhibitor and/or corticosteroid injections in the TMJ any time for at least six months between onset and the panoramic examination.
  7. Number of “medication periods” = “potent medication” for six months or more between onset and the panoramic examination.
  8. “MTX and TNF-alpha inhibitor any time” = intake of MTX and TNF-alpha any time for at least six months between onset and the panoramic examination.
  9. “EU 1 and/or potent medication” any time = EU1 and/or potent medication for at least six months between onset and the panoramic examination.